linjc16/ctgov huggingface dataset:
Immunological Characterization of Bronchoalveolar Cells in Normals

Study Overview
=================
Brief Summary
-----------------
To obtain the monocytes (white blood cells) from normal volunteers for the purpose of studying how proteins, fats, carbohydrates, as well as RNA and DNA for gene expression, relate to immunity. This information will be compared to other studies in patients with lung diseases such as Emphysema, Sarcoidosis, and Interstitial Pulmonary Fibrosis.

Detailed Description
-----------------
To determine the functional capabilities of cells obtained from bronchoalveolar lavage fluid and peripheral blood monocytes from normal individuals. The ongoing objective varies from investigation to investigation but in general the investigational goals are to better understand the immune function of monocytes purified from normal volunteers. In some instances the emphasis will be upon comparing the specific immune function (e.g. ability to sense endotoxin and release a cytokine) from blood monocytes as compared to human alveolar macrophages. This comparison is not the only goal of the study, however. In many cases the immune function of the monocyte will be sufficient in and of itself as an investigational goal. In other cases the same is true of alveolar macrophage function.

Official Title
-----------------
Immunological Characterization of Bronchoalveolar Cells in Normals

Conditions
-----------------
Lung Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy Exclusion Criteria: unable to consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| comparing the specific immune function (e.g. ability to sense endotoxin and release a cytokine) from blood monocytes as compared to human alveolar macrophages |  | end of study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analysis of lung proteins present in BAL fluid |  | end of study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Emphysema, Sarcoidosis, Interstitial Pulmonary Fibrosis
Prospective Comparison of Cirrus Versus Stratus Ocular Coherence Tomography for Different Retinal Pathology.

Study Overview
=================
Brief Summary
-----------------
Ocular Coherence Tomography (OCT) is a non-invasive ophthalmologic test that uses reflected, unheated, non-concentrated visible light in order to scan and provide a 2-dimensional topographic analysis of the retina and optic nerve. It has wide diagnostic utility especially in patients with clinically significant macular edema, glaucoma, and other retinal eye diseases. At the University of Chicago, we have utilized the Stratus brand OCT (Carl Zeiss Inc) for the past 5 years. Recently we have acquired a beta version of the company's new model, the Cirrus HD-OCT (Carl Zeiss Inc.) which features improved resolution, shorter scanning time and a more user-friendly interface. The purpose of this study is to compare findings between the two models in patients with different common and uncommon eye diseases, including diabetic macular edema, glaucoma and age-related macular degeneration. We hypothesis that the Cirrus OCT is able to accurately quantify eye pathology compared to Stratus OCT.

Official Title
-----------------
Prospective Comparison of Cirrus and Stratus Optical Coherence Tomography for Quantifying Retinal Thickness

Conditions
-----------------
Retinal Pathology

Intervention / Treatment
-----------------
* Device: Optical coherance tomography ( Cirrus; Stratus)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any eye pathology that may cause macular edema. Exclusion Criteria: Vitreous media opacities including dense cataracts, vitreous hemorrhage, and corneal opacities

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Optical coherance tomography ( Cirrus; Stratus)|Non-contact retinal thickness analyzer|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
OCT;, Cirrus;, Stratus;, macular thickness
The Effect of Digital Breast Tomosynthesis in Breast Cancer Long-term Survival: a Single Institution Study

Study Overview
=================
Brief Summary
-----------------
To investigate whether digital breast tomosynthesis (DBT) benefits survival improvement.

Detailed Description
-----------------
To suggest DBT for specific populations, compare the overall survival rate of women with digital mammography (DM) to the DBT screening for women with particular characteristics.

Official Title
-----------------
The Effect of Digital Breast Tomosynthesis in Breast Cancer Long-term Survival: a Single Institution Study

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Device: DBT
* Device: DM


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: individuals were diagnosed with breast cancer according to the International Disease Classification Criteria Exclusion Criteria: no surgery or incomplete surgical pathology stage complete remission after neoadjuvant chemotherapy non-breast cancer death bilateral breast cancer male breast cancer no pre-surgery mammography image

Ages Eligible for Study
-----------------
Minimum Age: 23 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Screening cohort<br>Women received mammography screening | Device: DBT<br>* Image with digital breast tomosynthesis<br>* Other names: Digital Breast Tomosynthesis;Device: DM<br>* Image with digital mammography<br>* Other names: Digital Mammography;|
| Diagnostic cohort<br>Women received clinical breast examination | Device: DBT<br>* Image with digital breast tomosynthesis<br>* Other names: Digital Breast Tomosynthesis;Device: DM<br>* Image with digital mammography<br>* Other names: Digital Mammography;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival rate | Compare the overall survival rate according to breast density type, cancer stage, mammography test type, and imaging modality. | Up to 111 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
breast cancer
Ultrasonographic Versus Renographic Parameters in Prediction of Early Success After Pyeloplasty in Children

Study Overview
=================
Brief Summary
-----------------
To study the predictive value of ultrasonographic (USG) parameters in the form of anteroposterior diameter , calyceal dilatation , calyx-to-parenchyma ratio , renal length , renal width , pelvis-to-cortex ratio (PCR) and parenchymal thickness versus renographic parameters in the form of T1/2 , differential renal function (DRF) and Tissue tracer transit (TTT) for early detection of children at risk of recurrent obstruction post unilateral pyeloplasty.

Official Title
-----------------
Ultrasonographic Versus Renographic Parameters in Prediction of Early Success After Pyeloplasty in Children. A Prospective Study.

Conditions
-----------------
Pyeloplasty, Pediatrics, Renogram, Ultrasonography

Intervention / Treatment
-----------------
* Diagnostic Test: Ultrasonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who will be scedueled for pyeloplasty Exclusion Criteria: bilateral pathology Pelvi-ureteric junction obstruction (PUJO) in a solitary kidney other associated anomalies

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Ultrasonography<br>Renal Ultrasonography | Diagnostic Test: Ultrasonography<br>* Renal Ultrasonography<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| evaluate predictive value of ultrasonographic parameters for early detection of recurrent obstruction | assessed by Diuretic scintigraphy (T1/2) as the time it takes for the activity in the kidney to decrease to 50% of its maximum value measured in minutes | 30 months | 
| evaluate predictive value of ultrasonographic parameters for early detection of decrease renal function | assessed by Diuretic scintigraphy differential renal function (DRF) measured in millilitres/minute | 30 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ultrasonography, Pyeloplasty, Renogram, Follow up
Preeclampsia-like Syndrome Induced by COVID-19: Is it a Real Public Health Issue in Pregnancy During the Pandemic?

Study Overview
=================
Brief Summary
-----------------
By applying polymerase chain reaction (PCR) test for Covid-19 to preeclampsia patients who applied to our hospital during the Covid-19 pandemic period, we investigated the frequency of Covid-19 related preeclampsia-like syndrome in this patient group.

Detailed Description
-----------------
The investigators studied the frequency of Covid-19 related preeclampsia-like syndrome by PCR test and lung ultrasound for Covid-19 to preeclampsia patients presenting to the instutution during the Covid-19 pandemic period. The first consecutive 100 preeclampsia patients presented to our hospital during the pandemic will be involved in our study. The primary outcome measure is to detect Covid-19 positivity among the preeclamptic pregnant women..

Official Title
-----------------
Evaluation of COVID-19 Incidence in Patients With Preeclampsia During Pandemic

Conditions
-----------------
Covid-19, Preeclampsia, Pregnancy Related

Intervention / Treatment
-----------------
* Diagnostic Test: PCR, lung ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: First consecutive 100 pregnant women presenting with preeclamptic symptoms and signs between March 15, 2020 and June 1, 2020. Exclusion Criteria: The pregnancies with known diagnosis of preeclampsia before Covid-19 pandemic Preeclamptic patient without a Covid-19 PCR test result Pregnant women who does not want to participate in study or does not want their personal informations to be shared Pregnant women less than 18 years old and more than 40 years old are excluded

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: PCR, lung ultrasound|PCR for Covid-19|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PCR positivity | To detect Covid-19 PCR test positivity among preeclamptic pregnant women | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
covıd-19, pregnancy, preeclampsia, preeclampsia-like syndrome
Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to determine whether impaired glucose tolerance is improved to a greater degree by Tarka than Hyzaar in subjects with metabolic syndrome

Official Title
-----------------
A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Hyzaar® on Glucose Tolerance in Subjects With Metabolic Syndrome

Conditions
-----------------
Hypertension, Metabolic Syndrome

Intervention / Treatment
-----------------
* Drug: trandolapril/verapamil
* Drug: (Hyzaar) losartan/hydrochlorothiazide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Metabolic syndrome Fasting blood glucose between 100 mg/dL and 125 mg/dL Hypertension One additional criteria, Exclusion 1 Exclusion Criteria: Subject has a current diagnosis of Type 1 or Type 2 diabetes mellitus. Subject has a hypersensitivity to ACE inhibitor, ARB, CCB, clonidine, methyldopa, hydralazine, or thiazide diuretic medication.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br> | Drug: trandolapril/verapamil<br>* 2/180 mg QD with titration if needed at Week 4 to 4/240 mg QD<br>* Other names: Tarka;|
| Active Comparator: 2<br> | Drug: (Hyzaar) losartan/hydrochlorothiazide<br>* 50/12.5 mg QD with titration if needed at Week 4 to 100/25 mg QD<br>* Other names: losartan/hydrochlorothiazide;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oral Glucose Tolerance |  | up to 1 year / 52 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in blood pressure (BP), pulse rate and BP control. HbA1c, insulin sensitivity, insulin release, albuminuria, lipid profile, AMBP, clinical safety labs and adverse events. |  | up to 1 year / 52 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypertension, Metabolic Syndrome, Tarka, Hyzaar
The Impact of Rehabilitation on Quality of Life in Visually Impaired

Study Overview
=================
Brief Summary
-----------------
The project has four primary objectives: 1) Determine if blind rehabilitation improves the quality of life of legally blind veterans; 2) Determine the relationship between quality of life and visual function; 3) Determine if factors, such as cognitive status, level of depression, age and the presence of additional medical conditions besides vision loss, intervention of blind rehabilitation extends beyond the visually impaired individual and improve the quality of life of their primary caregiver (e.g. spouse, partner, family member or friend.)

Official Title
-----------------
The Impact of Rehabilitation on Quality of Life in Visually Impaired

Conditions
-----------------
Blindness

Intervention / Treatment
-----------------
* Procedure: Blindness


Participation Criteria
=================
Eligibility Criteria
-----------------
Visually impaired

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Blindness|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vision, quality of life
A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin

Study Overview
=================
Brief Summary
-----------------
Patient charts will be reviewed to evaluate the incidence of intraocular pressure spikes while on Loteprednol etabonate ophthalmic suspension 0.5%, Loteprednol etabonate (0.5%) and tobramycin (0.3%)

Conditions
-----------------
Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: Loteprednol etabonate ophthalmic suspension 0.5%
* Drug: Loteprednol etabonate (0.5%) and tobramycin (0.3%).


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient who experienced an IOP spike while using Lotemax or Zylet will be included Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Loteprednol etabonate ophthalmic suspension 0.5% | Drug: Loteprednol etabonate ophthalmic suspension 0.5%<br>* Apply one to two drops of Loteprednol etabonate ophthalmic suspension 0.5% into the conjunctival sac as prescribed by your physician<br>* Other names: LOTEMAX®;|
| 2<br>Loteprednol etabonate (0.5%) and tobramycin (0.3%) | Drug: Loteprednol etabonate (0.5%) and tobramycin (0.3%).<br>* Apply one or two drops of Loteprednol etabonate (0.5%) and tobramycin (0.3%) into the conjunctival sac as prescribed by your physician.<br>* Other names: Zylet®;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean Elevated Intraocular Pressure (IOP) During Treatment | Mean elevated IOP during treatment. IOP is a measurement of the fluid pressure inside the eye. IOP was recorded any time an elevation of IOP (increase of 5 mmHg or more) occurred while using study treatment. The median duration of treatment at the time of observed IOP elevation was 55 days. | 55 days |
The Role of Balneotherapy in Obese Patients With Knee Osteoarthritis

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to evaluate the role of balneotherapy in obese patients with knee osteoarthritis in terms of pain relief, improving joint function and deambulation, on endocrinological parameters, quality of life and of reduction the costs to Servizio Sanitario Nazionale (NHS).

Conditions
-----------------
Knee Osteoarthritis, Obesity

Intervention / Treatment
-----------------
* Other: Balneotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: obesity II-III grade (BMI 35-45 kg/m2) knee pain patient compliance to the treatment Exclusion Criteria: BMI<34,9kg/m2 or BMI> 45,1kg/m2 previous knee surgery complicated diabetes mellitus ischemic cardiomyopathy and heart failure acute phase of osteoarthritis varicose veins, deep venous thrombosis (DVT) cancer cutaneous lesions NSAIDs administration <1 week before the treatment knee infiltration <2 months before the treatment

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Balneotherapy<br>16 balneotherapy treatments, each of 45 minutes, twice a week, for 8 consecutive weeks | Other: Balneotherapy<br> <br> |
| No Intervention: Physiotherapy<br>16 physiotherapy treatments (no balneotherapy), each of 45 minutes, twice a week, for 8 consecutive weeks | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knee pain measurement with Visual Analogue Scale (VAS) |  | At the begining and at the end of the treatment. After 6 months of the end of therapy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knee range of motion |  | At the begining and at the end of the treatment. After 6 months of the end of therapy |
Clinical and Laboratory Predictors of Respiratory Morbidities in CP Children

Study Overview
=================
Brief Summary
-----------------
Relationship between respiratory morbidities and cerebral palsy in children

Detailed Description
-----------------
Identification of symptoms,signs,severity and outcomes of respiratory morbidities in children with Cp

Official Title
-----------------
Clinical and Laboratory Predictors of Respiratory Morbidities in Children With Cerebral Palsy at Assiut University Children Hospital

Conditions
-----------------
Recurrent Respiratory Tract Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children with CP from 1 month to 18 years Exclusion Criteria: neonates with Cp CP patients more than 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Chest auscultation | Identify any respiratory abnormalities in CP patients | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Chest X-ray | Identify any chest infection in CP patients | Baseline |